Ryan Culler, originally interested in astronomy, shifted his focus to cancer research. Culler has recently taken the helm as the production medical isotope program manager for the Isotope Processing and Manufacturing Division (IPMD) at Oak Ridge National Laboratory, as reported by ORNL's newsroom.
The decision to join IPMD was not one taken lightly by Culler, who had to pivot away from a secure path with Colgate Palmolive. His drive to work in a field that holds deep personal significance was strong enough to make this move. "Anything I can do to fight cancer, that's what I want to do," Culler told ORNL. This commitment seems to stem from the loss of his brother to pancreatic cancer nearly a decade ago—a loss that continues to fuel his motivation today.
At IPMD, Culler's involvement is strategic and impactful; he's working to oversee the standardization of the entire production line of the isotope actinium-225 (Ac-225), a promising cancer-fighting agent. It was under IPMD's guidance that Ac-225 became the first in hopes to be a long line of routine isotope productions established since the foundation of the division in 2022. Culler's approach reflects his expertise in Good Manufacturing Practices and FDA compliance, skills crucial to his role, and the broader mission of cancer treatment advancements.
Despite the professional shift, Culler has managed to stay grounded through his bond with his son. They share a love for activities like concerts, four-wheeling, and hunting. He prizes this relationship greatly, affirming, "He's my priority," as he remarked to ORNL.
Looking ahead, Culler and the IPMD aim to eventually allow private industry to take over the production of Ac-225, provided they can match the high purity standards set by ORNL. Oak Ridge National Laboratory, managed by UT-Battelle for the DOE’s Office of Science, continues to be pivotal in supporting such critical research.
